Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.

MLA

Pandya, Deep, et al. “Treatment-Emergent Neuroendocrine Prostate Cancer with a Germline BRCA2 Mutation: Identification of a Candidate Reversion Mutation Associated with Platinum/PARP-Inhibitor Resistance.” Cold Spring Harbor Molecular Case Studies, vol. 7, no. 1, Feb. 2021, pp. 1–12. EBSCOhost, https://doi.org/10.1101/mcs.a005801.

APA

Pandya, D., Shah, M., Kaplan, F., Martino, C., Levy, G., Kazanjian, M., Batter, S., Martignetti, J., & Frank, R. C. (2021). Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance. Cold Spring Harbor Molecular Case Studies, 7(1), 1–12. https://doi.org/10.1101/mcs.a005801

Chicago

Pandya, Deep, Myra Shah, Fuat Kaplan, Candice Martino, Gillian Levy, Mia Kazanjian, Stephen Batter, John Martignetti, and Richard C. Frank. 2021. “Treatment-Emergent Neuroendocrine Prostate Cancer with a Germline BRCA2 Mutation: Identification of a Candidate Reversion Mutation Associated with Platinum/PARP-Inhibitor Resistance.” Cold Spring Harbor Molecular Case Studies 7 (1): 1–12. doi:10.1101/mcs.a005801.